Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
Add more filters










Publication year range
1.
Biotechnol Prog ; 37(5): e3191, 2021 09.
Article in English | MEDLINE | ID: mdl-34218531

ABSTRACT

To increase the efficiency of aptamers to their targets, a simple and novel method has been developed based on aptamer oligomerization. To this purpose, previously anti-human TNF-α aptamer named T1-T4 was trimerized through a trimethyl aconitate core for neutralization of in vitro and in vivo of TNF-α. At first, 54 mer T1-T4 aptamers with 5'-NH2 groups were covalently coupled to three ester residues in the trimethyl aconitate. In vitro activity of novel anti-TNF-α aptamer and its dissociation constant (Kd ) was done using the L929 cell cytotoxicity assay. In vivo anti-TNF-α activity of new oligomerized aptamer was assessed in a mouse model of cutaneous Shwartzman. Anchoring of three T1-T4 aptamers to trimethyl aconitate substituent results in formation of the 162 mer fragment, which was well revealed by gel electrophoresis. In vitro study indicated that the trimerization of T1-T4 aptamer significantly improved its anti-TNF-α activity compared to non-modified aptamers (P < 0.0001) from 40% to 60%. The determination of Kd showed that trimerization could effectively enhance Kd of aptamer from 67 nM to 36 nM. In vivo study showed that trimer aptamer markedly reduced mean scar size from 15.2 ± 1.2 mm to 1.6 ± 0.1 mm (P < 0.0001), which prevent the formation of skin lesions. In vitro and in vivo studies indicate that trimerization of anti-TNF-α aptamer with a novel approach could improve the anti-TNF-α activity and therapeutic efficacy. According to our findings, a new anti-TNF-α aptamer described here could be considered an appropriate therapeutic agent in treating several inflammatory diseases.


Subject(s)
Aptamers, Nucleotide , Shwartzman Phenomenon/metabolism , Tumor Necrosis Factor Inhibitors , Tumor Necrosis Factor-alpha/metabolism , Animals , Aptamers, Nucleotide/chemistry , Aptamers, Nucleotide/metabolism , Aptamers, Nucleotide/pharmacology , Cell Line , Female , Mice , Mice, Inbred BALB C , Tumor Necrosis Factor Inhibitors/chemistry , Tumor Necrosis Factor Inhibitors/metabolism , Tumor Necrosis Factor Inhibitors/pharmacology
2.
Immunity ; 25(2): 271-83, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16872848

ABSTRACT

CD18 integrins promote neutrophil recruitment, and their engagement activates tyrosine kinases, leading to neutrophil activation. However, the significance of integrin-dependent leukocyte activation in vivo has been difficult to prove. Here, in a model of thrombohemorrhagic vasculitis, the CD18 integrin Mac-1 on neutrophils recognized complement C3 deposited within vessel walls and triggered a signaling pathway involving the Src-family kinase Hck and the Syk tyrosine kinase. This led to neutrophil elastase release, causing hemorrhage, fibrin deposition, and thrombosis. Mice genetically deficient in any of these components (C3, Mac-1, Hck, Syk, or elastase) were resistant to disease despite normal tissue neutrophil accumulation. Disease was restored in Mac-1-deficient mice infused with wild-type, but not kinase- or elastase-deficient, neutrophils. Elastase release in the inflamed tissue was reduced in Mac-1-deficient mice, and a deficiency of Mac-1 or the kinases blocked neutrophil elastase release in vitro. These data suggest that Mac-1 engagement of complement activates tyrosine kinases to promote elastase-dependent blood vessel injury in vivo.


Subject(s)
Intracellular Signaling Peptides and Proteins/metabolism , Macrophage-1 Antigen/metabolism , Pancreatic Elastase/metabolism , Protein-Tyrosine Kinases/metabolism , Shwartzman Phenomenon/metabolism , Signal Transduction , Thrombosis/metabolism , src-Family Kinases/metabolism , Animals , Cell Adhesion , Cell Movement , Complement C3/metabolism , Intercellular Adhesion Molecule-1/metabolism , Ligands , Macrophage-1 Antigen/genetics , Matrix Metalloproteinases/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , NADPH Oxidases/metabolism , Neutrophils/cytology , Neutrophils/enzymology , Peptide Hydrolases/metabolism , Reactive Oxygen Species/metabolism , Shwartzman Phenomenon/genetics , Shwartzman Phenomenon/pathology , Syk Kinase , Thrombosis/genetics , Thrombosis/pathology
3.
Bioorg Med Chem ; 9(5): 1279-91, 2001 May.
Article in English | MEDLINE | ID: mdl-11377186

ABSTRACT

A series of new water-soluble thalidomide prodrugs was prepared. All compounds were derivatized on the nitrogen of the glutarimide ring. Esters of natural amino acids and succinic acid derivatives have been introduced by reaction with the hydroxymethyl thalidomide 2. Nicotinic acid derivatives were prepared from halomethyl derivatives. Additionally, a methoxymethyl derivative and a carboxymethyl derivative were prepared directly from thalidomide. Most compounds showed a very large increase in water solubility compared to thalidomide itself (0.012mg/mL). The amorphous hydrochlorides of the N-methylalanine ester 8, valine ester 9, and glycylglycine ester 10, respectively, were the most soluble compounds showing solubility greater than 300mg/mL, which equals an increase greater than 15,000-fold. The lipophilicity of the prodrugs has been determined by their HPLC capacity factors k'. The stability of selected compounds was determined. The hydrolysis rates follow pseudo-first order kinetics. In order to assess the immunological activity, the prodrugs were tested using tumor necrosis factor-alpha and interleukin-2 inhibition assays. Selected compounds were additionally investigated on their abililty to inhibit the local Shwartzman reaction, an assay to determine the vascular permeability. The prodrugs retained high effectiveness in the inhibition of TNF-alpha release. Our results indicated that the more stable prodrugs exhibited higher activity in the immunological assays. Some compounds showed higher activity than thalidomide itself, suggesting a high affine binding to the pharmacophore. In conclusion, the prodrugs exhibited high water solubility and high activity and might therefore be used in therapeutic applications.


Subject(s)
Interleukin-2/antagonists & inhibitors , Interleukin-2/biosynthesis , Shwartzman Phenomenon/metabolism , Thalidomide/chemical synthesis , Thalidomide/pharmacology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Animals , Binding Sites , Drug Stability , Humans , Hydrogen-Ion Concentration , Hydrolysis , Kinetics , Male , Mice , Permeability , Solubility , Thalidomide/chemistry , Water/chemistry
4.
Clin Exp Immunol ; 114(3): 491-9, 1998 Dec.
Article in English | MEDLINE | ID: mdl-9844062

ABSTRACT

Vascular injury in vasculitis may be due to activation of circulating neutrophils resulting in their increased adhesiveness to locally activated endothelium (Shwartzman phenomenon). Previously, we demonstrated up-regulation of endothelial intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in biopsies from patients with ANCA-associated vasculitis. In the present study, we investigated the expression of adhesion molecules (CD11b, ICAM-1, VLA-4, L-selectin) and activation markers (CD66b, CD64, CD63) on circulating neutrophils from patients with ANCA-associated vasculitis in comparison with their expression on cells from healthy volunteers and patients with sepsis. We related these findings to parameters of disease activity. Surface marker expression was determined by using a non-activating whole blood flow cytometric assay. The expression of activation markers, but not the expression of adhesion molecules, was increased on neutrophils from patients with active vasculitis. The expression of CD63 and CD66b on neutrophils correlated with disease activity as determined by the Birmingham Vasculitis Activity Score (BVAS). In contrast to patients with active vasculitis, patients with sepsis showed up-regulation of all markers, including adhesion molecules, suggesting that circulating neutrophils are fully activated in sepsis. We conclude that in ANCA-associated vasculitis, circulating neutrophils are not fully activated, since they do not express increased levels of adhesion molecules as sepsis or in the Shwartzman reaction. These findings are compatible with the concept that in vivo vascular damage in ANCA-associated vasculitides does not occur due to a Shwarzman-like reaction but only after ANCA-induced neutrophil activation at the endothelial cell surface.


Subject(s)
Antibodies, Antineutrophil Cytoplasmic , Cell Adhesion Molecules/biosynthesis , Neutrophil Activation , Neutrophils/immunology , Shwartzman Phenomenon/immunology , Adult , Aged , Aged, 80 and over , Biomarkers , Female , Humans , Male , Middle Aged , Shwartzman Phenomenon/metabolism
5.
FEMS Immunol Med Microbiol ; 12(3-4): 165-74, 1995 Dec.
Article in English | MEDLINE | ID: mdl-8745000

ABSTRACT

The Shwartzman reaction is an animal model displaying histopathological vasculitis phenomena. Extravasation and swelling due to increased vascular permeability and cellular infiltration, which are hallmarks of the Shwartzman reaction, were evaluated as leakage of i.v.-injected Evans Blue dye and by histological and immunohistological characteristics in rabbits and mice. (+/-)-Thalidomide, (-)-thalidomide, (+)-thalidomide and dexamethasone inhibited the increase of vascular permeability in the local Shwartzman reaction. Histologically, the intensity of the Shwartzman reaction was reduced. In mice thrombus formation and leukocytoclastic vasculitis was inhibited by (+/-)-thalidomide and (+)-thalidomide. ICAM-1 expression was markedly reduced after (+)-thalidomide injection. Thalidomide and dexamethasone pretreatment reduced Mac-1 expression on perivascular infiltrated granulocytes. The inhibitory effect of thalidomide on vasculitis of the Shwartzman reaction may thus be related to reduction of adhesion molecule expression.


Subject(s)
Shwartzman Phenomenon/metabolism , Shwartzman Phenomenon/pathology , Thalidomide/pharmacology , Animals , Capillary Permeability/drug effects , Dexamethasone/pharmacology , Intercellular Adhesion Molecule-1/biosynthesis , Macrophage-1 Antigen/biosynthesis , Male , Mice , Mice, Inbred BALB C , Mice, Inbred Strains , Rabbits
6.
J Clin Invest ; 96(5): 2339-47, 1995 Nov.
Article in English | MEDLINE | ID: mdl-7593621

ABSTRACT

Previous studies in vivo have shown that IL-10 infusion can prevent lethal endotoxic shock. Mice deficient in the production of IL-10 (IL10T) were used to investigate the regulatory role of IL-10 in the responses to LPS in three experimental systems. In a model of acute endotoxic shock, it was found that the lethal dose of LPS for IL10T mice was 20-fold lower than that for wild type (wt) mice suggesting that endogenous IL-10 determines the amount of LPS which can be tolerated without death. The high mortality rate of IL10T mice challenged with modest doses of LPS was correlated to the uncontrolled production of TNF as treatment with anti-TNF antibody (Ab) resulted in 70% survival. Additional studies suggested that IL-10 mediates protection by controlling the early effectors of endotoxic shock (e.g., TNF alpha) and that it is incapable of directly antagonizing the production and/or actions of late appearing effector molecules (e.g., nitric oxide). We also found that IL10T mice were extremely vulnerable to a generalized Shwartzman reaction where prior exposure to a small amount of LPS primes the host for a lethal response to a subsequent sublethal dose. The priming LPS dose for IL10T mice was 100-fold lower than that required to prime wt mice implying that IL-10 is important for suppressing sensitization. In agreement with this assumption, IL-10 infusion was found to block the sensitization step. Interestingly, IL-10 was not the main effector of endotoxin tolerance as IL10T mice could be tolerized to LPS. Furthermore, IL-10 infusion could not substitute for the desensitizing dose of LPS. These results show that IL-10 is a critical component of the host's natural defense against the development of pathologic responses to LPS although it is not responsible for LPS-induced tolerance.


Subject(s)
Endotoxins/toxicity , Interleukin-10/deficiency , Lipopolysaccharides/toxicity , Shock, Septic/metabolism , Shwartzman Phenomenon/metabolism , Animals , Drug Tolerance , Escherichia coli , Mice , Mice, Inbred C57BL
7.
J Lipid Mediat Cell Signal ; 10(3): 229-42, 1994 Sep.
Article in English | MEDLINE | ID: mdl-7812674

ABSTRACT

Evidence indicates a role for platelet-activating factor (PAF) in endotoxin (LPS)-induced shock. To determine its involvement in LPS-induced intravascular coagulation, we assessed the efficacy of SRI 63-675, a specific PAF receptor antagonist, to prevent fibrin deposition in the various organs of New Zealand White rabbits 4 h after two intravenous doses of LPS (100 micrograms/kg), spaced 24 h apart. SRI 63-675 significantly lowered peak tumor necrosis factor levels after LPS challenge. Administration of SRI 63-675 around either the first (150 mg/kg) or second LPS dose (120 mg/kg), however, did not prevent coagulation. The unexpected high mortality after combined administration of SRI 63-675 and LPS precluded assessment of PAF inhibition around both LPS doses on coagulation. Sole administration of SRI 63-675 induced rapid and transient changes in peripheral blood cell counts, and blood pressure and heart rate suggestive of intrinsic PAF-like activity. Although some other intrinsic toxic effect of SRI 63-675 cannot be ruled out, it is suggested that endotoxin may have primed the rabbit to the lethal, PAF-like, effects of SRI 63-675.


Subject(s)
Platelet Membrane Glycoproteins/antagonists & inhibitors , Quinolines/therapeutic use , Receptors, Cell Surface , Receptors, G-Protein-Coupled , Shwartzman Phenomenon/prevention & control , Animals , Blood Cell Count/drug effects , Drug Interactions , Female , Hematocrit , Hemodynamics/drug effects , Kidney/drug effects , Kidney/pathology , Lipopolysaccharides/toxicity , Platelet Activating Factor/antagonists & inhibitors , Quinolines/toxicity , Rabbits , Shwartzman Phenomenon/metabolism , Tumor Necrosis Factor-alpha/metabolism
8.
Arthritis Rheum ; 37(3): 376-83, 1994 Mar.
Article in English | MEDLINE | ID: mdl-7510492

ABSTRACT

OBJECTIVE: To test the hypothesis that during exacerbations of systemic lupus erythematosus (SLE), endothelial cells are activated to increase their expression of adhesion molecules. METHODS: Endothelial cell expression of E-selectin, vascular cell adhesion molecule 1 (VCAM-1), and intercellular adhesion molecule 1 (ICAM-1) was quantitated immunohistochemically in 20 biopsy specimens from nonlesional, non-sun-exposed skin from 16 SLE patients. Disease activity was evaluated with the SLE Disease Activity Index (SLEDAI) and with measurements of complement components C3a desArg, C3, and C4. RESULTS: The mean expression of all 3 adhesion molecules was significantly elevated in patients with SLE versus healthy controls, as well as in patients with active versus inactive SLE. The mean C3a desArg level was significantly higher in patients with active SLE compared with those with inactive SLE. The SLEDAI scores correlated directly with C3a desArg levels and inversely with C3 and with C4 levels. Evaluation of serial biopsy specimens demonstrated loss of endothelial cell adhesion molecules and reduction of C3a levels with clinical improvement. CONCLUSION: Our findings demonstrate up-regulation of the surface expression of 3 distinct adhesion molecules, E-selectin, VCAM-1, and ICAM-1, in patients with SLE. The abnormal expression of these endothelial cell adhesion molecules is most marked in patients with active disease characterized by significant elevations of the complement split product C3a desArg. We suggest that in certain SLE patients, excessive complement activation in association with primed endothelial cells induces leukocyte-endothelial cell adhesion and leuko-occlusive vasculopathy.


Subject(s)
Cell Adhesion Molecules/metabolism , Endothelium, Vascular/metabolism , Lupus Erythematosus, Systemic/metabolism , Shwartzman Phenomenon/metabolism , Up-Regulation , Complement C3/metabolism , Complement C3a/analogs & derivatives , Complement C3a/metabolism , Complement C4/metabolism , E-Selectin , Humans , Immunohistochemistry , Intercellular Adhesion Molecule-1 , Lupus Erythematosus, Systemic/pathology , Skin/metabolism , Skin/pathology , Vascular Cell Adhesion Molecule-1
9.
Diabetes ; 39(1): 83-6, 1990 Jan.
Article in English | MEDLINE | ID: mdl-2210064

ABSTRACT

The effect of cyclosporin (CsA) on the endotoxin-induced generalized Shwartzman reaction (GSR) was studied in diabetic and nondiabetic rats. After 4.5 wk of diabetes, CsA (20 mg/kg) or intralipid as a control substance was given intraperitoneally daily for 10 days. Next, diabetic rats were given either high-dose (2 mg/kg or low-dose (0.1 mg/kg) endotoxin (Escherichia coli 026:B6 lipopolysaccharide B) as a single injection. The rats were killed at intervals of 1, 4, 8, and 24 h. No significant glomerular thrombi were seen in the nondiabetic control animals, whereas the severity of glomerular thrombi in the diabetic animals was dependent on the presence or absence of CsA, endotoxin dose, and degree of glycemic control. In the diabetic rats, glomerular thrombi occurred maximally at 4 h but were no longer present at 24 h. The CsA/high-dose-endotoxin rats had fewer glomerular thrombi than rats receiving the intralipid/high-dose endotoxin, but this difference was not statistically significant. The CsA/low-dose-endotoxin rats had increased glomerular thrombi compared with the intralipid/low-dose-endotoxin rats (P less than 0.01). Insulin treatment reduced the glomerular capillary thrombi in the CsA/low-dose-endotoxin diabetic animals. Thus, CsA aggravates the GSR with low-dose endotoxin but has no significant effect when high-dose endotoxin is given. Improved glycemic control reduces the GSR in CsA-treated rats. Thus, the interrelationships of diabetes, endotoxin, and CsA on the GSR are complex, and the pathogenesis of these events is unclear.


Subject(s)
Cyclosporins/pharmacology , Diabetes Mellitus, Experimental/metabolism , Shwartzman Phenomenon/metabolism , Animals , Cyclosporins/adverse effects , Diabetes Mellitus, Experimental/chemically induced , Diabetes Mellitus, Experimental/physiopathology , Disease Models, Animal , Dose-Response Relationship, Drug , Endotoxins/adverse effects , Endotoxins/pharmacology , Female , Rats , Rats, Inbred Strains , Shwartzman Phenomenon/physiopathology , Thrombosis/chemically induced , Thrombosis/metabolism , Thrombosis/physiopathology
10.
Kidney Int ; 32(1): 31-8, 1987 Jul.
Article in English | MEDLINE | ID: mdl-3306097

ABSTRACT

Fibrin formation in the kidney is frequently associated with clinically-significant renal dysfunction. We therefore measured and characterized the procoagulant activity (PCA) which is present in normal kidneys and in kidneys of rabbits with the Shwartzman phenomenon induced by two injections of bacterial lipopolysaccharide (LPS; E. coli LPS 055:B5,25 micrograms/kg and 50 micrograms/kg administered 24 hrs apart with rabbits sacrificed 12 hrs after the second injection). PCA was measured in sonicated tissue by one-stage coagulation assay. In normal kidneys the amounts of PCA in the inner medulla, outer medulla and inner cortex were 18.2 +/- 3.2, 44.1 +/- 3.8 and 78.5 +/- 5.7 percent, respectively, of that in the outer cortex (N = 31). Glomeruli (purified by the iron oxide magnetic method to greater than 95 percent homogeneity) contained 21.6 +/- 8.8 arbitrary units/micrograms protein compared with tubular fragments which contained 13.9 +/- 2.6 U/micrograms protein (N = 9). In LPS-treated rabbits PCA (in units/micrograms) increased in outer cortex from 33.7 +/- 3.9 (control) to 73.4 +/- 10.4 (LPS, P less than 0.01), in inner cortex from 26.7 +/- 2.9 (control) to 83.3 +/- 17 (LPS, P less than 0.02), in outer medulla from 12.9 +/- 2.4 (control) to 54.5 +/- 16.5 (LPS, P less than 0.05), and in inner medulla from 12.2 +/- 2.4 (control) to 32.1 +/- 4.9 (LPS, P less than 0.01). Glomerular PCA increased from 21.6 +/- 8.8 (control) to 88.8 +/- 20.7 (LPS) units/micrograms (P = 0.01), while tubular fragment preparation PCA increased from 13.9 +/- 2.6 (control) to 44.6 +/- 12.7 (LPS) U/micrograms (P = 0.02) (N = 9 per group).(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Blood Coagulation , Kidney Diseases/metabolism , Shwartzman Phenomenon/metabolism , Animals , Capillaries/metabolism , Escherichia coli , Fibrin/metabolism , Interleukin-1 , Kidney Diseases/etiology , Kidney Glomerulus/blood supply , Kidney Glomerulus/metabolism , Lipopolysaccharides , Male , Rabbits
11.
Thromb Res ; 42(3): 323-9, 1986 May 01.
Article in English | MEDLINE | ID: mdl-3715805

ABSTRACT

Homogenized arterial walls of rabbits were shown to possess significant amounts of thromboplastin activity. The specific activity, percent activity per mg tissue, varied in different arteries. Thus the thromboplastin activity of the carotid was found to be about ten-fold higher compared to the femoral. Thromboplastin activity measurements of different organs revealed a very high level of thromboplastin in lung, whereas kidney and spleen had respectively 6 and 25 times less activity than the lung. Induction of generalized Shwartzman reaction by giving two doses of endotoxin 24 hours apart, caused no significant rise in thromboplastin activity of either arteries or organs, but induced a 35-fold increase of thromboplastin activity of circulating monocytes. The very high thromboplastin activity in the lung probably reflects the widespread and dense population of vessel in this particular organ. It is concluded that the amount of thromboplastin present in the vessel wall gives the possibility for a potent activation of the clotting system in normal haemostasis.


Subject(s)
Arteries/analysis , Shwartzman Phenomenon/metabolism , Thromboplastin/analysis , Animals , Female , Hemostasis , Kidney/analysis , Leukocyte Count , Lung/analysis , Male , Rabbits , Spleen/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...